3World Health Organization.The World Health Report:Conquering suffering,enriching humanity[M].Geneva:WHO,1997,6.
4Schoonjans K,Martin G,Staels B,et al.Peroxisome proliferator activated receptors,orphans with ligands and fanctions[J].Curr Op in Lipidol,1997, 8 (1) :159-66.
5Spiegelman B M.PPAR-r,A dipogenic regulator and thiazolidinedione receptor[J].Diabetes,1998, 47 (4) :507-14.
6DigybJ E,Montague CT,Stewter C P,et al.Thiazolidinediones exposure increases the expression of uncoupling protein in cultured human preadipocytes[J].Diabetes,1998,47(1):138-41.
7Bjorntorp P,Metabolic implications of body fat distribution.Diabetes-Care1991,14:1132.
8Dunaif A.Insulin resistance and the polycystic ovary syndrome mechanism and implications for pathogenesis.Endocr Rev,1997,18:774-800.
9Ehrmann DA,Schneider DJ,Sobel BE,et al.Troglitazone improves defects in insulin action,insulin secretion,ovarian steroidogenesis,and fibrinolysis in women with polycystic ovary syndrome.J Clin Endocrinol Metab,1997,82:2108-16.
10Mitwally M,Kuscu N,Yalcinkaya TM.High ovulatory rates with use of roglitazone in clomiphene resistant women with polycystic ovary syndrome.Hum Reprod,1999,14:2700-03
